id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2020-E-2325-0005,FDA,FDA-2020-E-2325,"Determination of Regulatory Review Period for Purposes of Patent Extension; ROZLYTREK TABLETS, New Drug Application 212725",Notice,Determinations,2022-08-02T04:00:00Z,2022,8,2022-08-02T04:00:00Z,2022-10-04T03:59:59Z,2024-04-05T17:31:19Z,2022-16504,0,0,0900006485204a88
FDA-2020-E-2325-0004,FDA,FDA-2020-E-2325,Letter from FDA CDER to U.S.  Patent and Trademark Office,Other,Letter(s),2022-06-14T04:00:00Z,2022,6,2022-06-14T04:00:00Z,,2024-01-25T14:03:08Z,,0,0,0900006485162e37